SM

Subhankar Mukhopadhyay

Active Director Director DIN 09339646
DIN 09339646 First appointment Sep 2021 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Subhankar Mukhopadhyay

Data last updated:

Subhankar Mukhopadhyay is a Director at Octagen Kiddle Biologics Private Limited (since 2021). The company operates in Healthcare.

DIN 09339646
Primary Designation Director
Industry Healthcare
First Appointment 29 Sep 2021
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Sep 20212021Active

Directorship timeline

Open interactive timeline →
Octagen Kiddle Biologics Private Limited
Premium access

Shareholding and investment profile for Subhankar Mukhopadhyay

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Subhankar Mukhopadhyay

Subhankar Mukhopadhyay currently holds 1 directorship: Octagen Kiddle Biologics Private Limited (Director, since 29 Sep 2021).

Subhankar Mukhopadhyay was first appointed on 29 Sep 2021 as Director at Octagen Kiddle Biologics Private Limited.

The current boards of Subhankar Mukhopadhyay's companies include Gourav Kumar Mukerjee (Octagen Kiddle Biologics Private Limited), Partha Pratim Banerjee (Octagen Kiddle Biologics Private Limited), Santosh Kumar Yadav (Octagen Kiddle Biologics Private Limited), Suvankar Ray (Octagen Kiddle Biologics Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available